What is the optimal treatment of localized pancreatic adenocarcinoma? Journal Article
| Authors: | Duffy, A.; O'Reilly, E. M. |
| Article Title: | What is the optimal treatment of localized pancreatic adenocarcinoma? |
| Abstract: | The term localized disease as it applies to pancreatic adenocarcinoma encompasses distinct entities associated with varied prognoses and therapeutic recommendations. These include three disease categories: (1) disease that is localized and resectable, (2) localized disease that is borderline resectable, and (3) unequivocally unresectable pancreatic adenocarcinoma, all representing a continuum. The incorporation of systemic chemotherapy into the management of pancreatic adenocarcinoma at all stages has become standard of care, and the basis for this is discussed with reference to the major clinical trial landmarks. The role of radiation therapy (in association with concomitant chemotherapy) in the management of localized pancreatic adenocarcinoma, however, has become less clear and represents an area of management confusion in this disease. Going forward, with the expectation of new and improved systemic agents, locoregional tumor control and, hence, chemoradiotherapy are anticipated to have a greater role and impact. |
| Keywords: | cancer surgery; survival rate; overall survival; clinical trial; drug tolerability; cancer localization; cancer recurrence; bevacizumab; cisplatin; erlotinib; fluorouracil; placebo; cancer combination chemotherapy; drug efficacy; drug safety; monotherapy; patient selection; treatment duration; unspecified side effect; antineoplastic agents; clinical trials as topic; capecitabine; gemcitabine; adjuvant therapy; cancer adjuvant therapy; cancer radiotherapy; combined modality therapy; pancreatic neoplasms; cancer staging; outcome assessment; antineoplastic agent; treatment indication; adenocarcinoma; drug eruption; multiple cycle treatment; radiotherapy; evidence based practice; combination chemotherapy; continuous infusion; cetuximab; survival time; folinic acid; drug response; patient safety; patient compliance; pancreas adenocarcinoma; pancreatectomy; platinum derivative; clinical effectiveness; inoperable cancer; platinum complex; cancer control; mitomycin; oxaliplatin; medical ethics; surgical anatomy; fluoropyrimidine derivative; portal vein; epidermal growth factor receptor kinase inhibitor; streptozocin; superior mesenteric vein |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 22 |
| Issue: | 11 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2008-10-01 |
| Start Page: | 1283 |
| End Page: | 1291 |
| Language: | English |
| PUBMED: | 18980025 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "CODEN: OCLGE" - "Source: Scopus" |
Citation Impact
Related MSK Work